{"id":"alks-2680-dose-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL579111","moleculeType":"Small molecule","molecularWeight":"478.64"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug selectively targets M1 muscarinic receptors in the brain, which are involved in cognition, attention, and memory. By acting as a partial agonist, it modulates cholinergic neurotransmission to improve cognitive deficits associated with schizophrenia and other neuropsychiatric conditions. This mechanism differs from typical antipsychotics by focusing on cognitive enhancement rather than dopamine antagonism alone.","oneSentence":"ALKS 2680 is a muscarinic M1 receptor partial agonist designed to enhance cognitive function and treat psychiatric symptoms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:47.490Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cognitive impairment associated with schizophrenia"},{"name":"Negative symptoms of schizophrenia"}]},"trialDetails":[{"nctId":"NCT07455383","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1","status":"NOT_YET_RECRUITING","sponsor":"Alkermes, Inc.","startDate":"2026-03","conditions":"Narcolepsy Type 1","enrollment":150},{"nctId":"NCT06358950","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2024-03-28","conditions":"Narcolepsy Type 1","enrollment":92}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Alixorexton"],"phase":"phase_3","status":"active","brandName":"ALKS 2680 Dose 1","genericName":"ALKS 2680 Dose 1","companyName":"Alkermes, Inc.","companyId":"alkermes-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ALKS 2680 is a muscarinic M1 receptor partial agonist designed to enhance cognitive function and treat psychiatric symptoms. Used for Cognitive impairment associated with schizophrenia, Negative symptoms of schizophrenia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}